NATICK, Mass.--(BUSINESS WIRE)--AffyImmune, a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR T cell therapies, presented preclinical data on ...
NATICK, Mass., Oct. 30, 2019 /PRNewswire/ -- AffyImmune Therapeutics, an emerging leader in CAR-T therapies, today announced FDA approval of the company's investigational new drug (IND) application ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results